Company News
AstraZeneca Elecoglipron Achieves 10.5% Weight Loss
AstraZeneca reported its experimental obesity pill elecoglipron produced a 10.5% average weight reduction after 26 weeks in a mid‑stage trial.
The highest daily dose achieved 11.8% weight loss over 36
